

Peter Ellmark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5595937/publications.pdf>

Version: 2024-02-01

16
papers

545
citations

840776

11
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

895
citing authors

#	ARTICLE	IF	CITATIONS
1	The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity. <i>Clinical Cancer Research</i> , 2015, 21, 1115-1126.	7.0	79
2	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
3	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 80-90.	3.4	78
4	Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. <i>Oncolmunology</i> , 2014, 3, e27614.	4.6	70
5	First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. <i>International Journal of Cancer</i> , 2019, 145, 1189-1199.	5.1	64
6	Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1-7.	4.2	33
7	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 47-60.	4.2	29
8	Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(l ³ -glutamic acid) nanoparticles. <i>Biomaterials</i> , 2012, 33, 6230-6239.	11.4	23
9	Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. <i>Oncolmunology</i> , 2020, 9, 1730538.	4.6	23
10	Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. <i>Immunology</i> , 2002, 106, 456-463.	4.4	17
11	Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1635-1646.	3.1	15
12	Kick-starting the cancer-immunity cycle by targeting CD40. <i>Oncolmunology</i> , 2015, 4, e1011484.	4.6	14
13	The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3629-3642.	4.2	11
14	Identification of a Strongly Activating Human Anti-CD40 Antibody That Suppresses HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 367-373.	1.1	7
15	858...A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies. , 2020, 8, A911-A911.		2
16	Selective Fcγ3R engagement by human agonistic anti-CD40 antibodies. <i>Translational Cancer Research</i> , 2016, 5, S839-S841.	1.0	1